The role and mechanism of epicardial adipose tissue in fibrosis and inflammation progress of atrial fibrillation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300069191

Enrollment

Unknown

Registered

2023-03-09

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

AF group:Epicardial adipose tissue obtain from mitral valve replacement or repair operation

SR group:Epicardial adipose tissue obtain from mitral valve replacement or repair operation

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: AF group: Patients with persistent atrial fibrillation who underwent mitral valve replacement or valve repairment SR group: patients with sinus rhythm who underwent mitral valve replacement or valve repairment Age: 18-70 years old

Exclusion criteria

Exclusion criteria: 1. Patients with malignant tumors; 2. Patients with paroxysmal atrial fibrillation; 3. Suffer from other types of cardiovascular disease; 4. Life expectancy is less than 1 year; 5, pregnancy; 6. Under 18 years old; 7. Severe hepatic and renal insufficiency; 8. Thyroid diseases; 9. Unwilling to accept the test and refuse to sign the informed consent

Design outcomes

Primary

Measure	Time frame
Single cell RNA sequencing of epicardial adipose tissue;electrocardiography;	—

Secondary

Measure	Time frame
blood routine;echocardiography;Inflammatory marker;	—

Countries

China

Contacts

Public ContactHu Tan, Jie Yang

Second Affiliated Hospital of Army Medical University

372534493@qq.com18623300911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026